ZC3H11A

Across TCGA pan-cancer cohorts, ZC3H11A mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ZC3H11A’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where ZC3H11A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ZC3H11A is over-expressed in tumor, although a few such as HNSC and CCRCC show the opposite, repressed pattern.

LSCC, LUAD, and HNSC are the cancer types where ZC3H11A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZC3H11A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Female	All	+1.425	<.001	9	view →
LUAD	Female	All	+1.265	<.001	9	view →
HNSC	All	IV	−0.616	.002	8	view →
CCRCC	All	All	−0.288	<.001	5	view →
PDAC	All	IV	+1.430	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ZC3H11A–LSCC

Open the LSCC breakdown →